Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells

Omid C. Farokhzad, Sangyong Jon, Ali Khademhosseini, Thanh-Nga T. Tran, David A. LaVan, and Robert Langer

Abstract

Nucleic acid ligands (aptamers) are potentially well suited for the therapeutic targeting of drug encapsulated controlled release polymer particles in a cell- or tissue-specific manner. We synthesized a bioconjugate composed of controlled release polymer nanoparticles and aptamers and examined its efficacy for targeted delivery to prostate cancer cells. Specifically, we synthesized poly(lactic acid)-block-polyethylene glycol (PEG) copolymer with a terminal carboxylic acid functional group (PLA-PEG-COOH), and encapsulated rhodamine-labeled dextran (as a model drug) within PLA-PEG-COOH nanoparticles. These nanoparticles have the following desirable characteristics: (a) negative surface charge (−50 ± 3 mV, mean ± SD, n = 3), which may minimize nonspecific interaction with the negatively charged nucleic acid aptamers; (b) carboxylic acid groups on the particle surface for potential modification and covalent conjugation to amine-modified aptamers; and (c) presence of PEG on particle surface, which enhances circulating half-life while contributing to decreased uptake in nontargeted cells. Next, we generated nanoparticle-aptamer bioconjugates with RNA aptamers that bind to the prostate-specific membrane antigen, a well-known prostate cancer tumor marker that is overexpressed on prostate acinar epithelial cells. We demonstrated that these bioconjugates can efficiently target and get taken up by the prostate LNCaP epithelial cells, which express the prostate-specific membrane antigen protein (77-fold increase in binding versus control, n = 150 cells per group). In contrast to LNCaP cells, the uptake of these particles is not enhanced in cells that do not express the prostate-specific membrane antigen protein. To our knowledge, this represents the first report of targeted drug delivery with nanoparticle-aptamer bioconjugates.

Introduction

The combination of targeted delivery and controlled drug release (1, 2) are potentially desirable properties when treating oncologic diseases where it is desirable that a cytotoxic dose of the drug is delivered to cancer cells over an extended period of time without killing the surrounding noncancerous tissue. Critical to achieving this goal is the engineering of specialized vehicles that encapsulate chemotherapy drugs for controlled release, and the targeting of these vehicles to cancer cells with ligands that recognize tumor-specific or tumor-associated antigens. A wide variety of targeting molecules have been assessed, with varying degrees of success, for their potential application in cancer therapy, including humanized antibodies and single-chain Fv generated from murine hybridoma or phage display, minibodies, and peptides (3). Interestingly, nucleic acid ligands, also called aptamers (4, 5), have emerged as a novel class of ligands that rival antibodies in their potential for therapeutic and diagnostic applications (6, 7). Aptamers are DNA or RNA oligonucleotides that fold by intramolecular interaction into unique three-dimensional conformations capable of binding to target antigens with high affinity and specificity. Considering the many favorable characteristics of aptamers, including small size, lack of immunogenicity, and ease of isolation, which together has resulted in their rapid progress into clinical trials (8), we became interested in examining these molecules for targeted delivery of controlled release polymer drug delivery vehicles.

As proof of concept we used RNA aptamers that bind to the prostate-specific membrane antigen (PSMA; ref. 9), a well-known transmembrane protein that is overexpressed on prostate cancer epithelial cells (10, 11), to develop specialized nanoparticle-aptamer bioconjugates for targeted delivery to prostate cancer cells. Prostate cancer is the single most common form of non–skin malignancy in men in the United States (12), and vehicles that target this disease for therapy may have a role in the management of this disease (13, 14). We used the following criteria for the development of our delivery vehicles: first, we were interested in developing drug encapsulated particles with a polymer system with components that were biocompatible, biodegradable, and approved by the Food and Drug Administration for a prior clinical use. Second, we were interested in developing particles that could be efficiently linked to the negatively charged nucleic acid aptamers using simple chemistry with minimal to no adverse effect on the three-dimensional conformation and ligand recognition properties of aptamers. Third, we were interested in developing delivery vehicles that demonstrate differentially high uptake efficiency by the targeted cells. Fourth, we were interested in developing vehicles with extended circulating half-life to increase the likelihood of their effectiveness in future therapeutic applications (15). We used rhodamine-labeled dextran (as a model drug) and developed drug encapsulated pegylated PLA nanoparticles with a negative surface charge. Using the PSMA aptamer, we developed nanoparticle-aptamer bioconjugates and then examined whether the targeting and uptake of these vehicles by prostate epithelial cells, which express the PSMA protein, could be achieved.

Materials and Methods

Materials. All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. Poly(D,L-lactic acid) (PLA; average Mw 25,000) was purchased from Boehringer Ingelheim (Ingelheim, Germany). The polyethylene glycol (PEG) polymer with a terminal hydroxyl and carboxylic acid functional groups (OH-PEG₃₄₀₀-COOH) was custom synthesized by Nektar Therapeutics (San Carlos, CA).

Synthesis of PLA-PEG-COOH. The D,L-lactide and OH-PEG₃₄₀₀-COOH were used to synthesize poly(D,L-lactide)-block-polyethylene glycol-COOH copolymer (PLA-PEG-COOH) by ring opening polymerization. The PLA-PEG₃₄₀₀-COOH was characterized by ¹H-NMR (400 MHz), δ = 5.28–5.11
Nanoparticle-Aptamer Conjugation. Fifty microliters of PLA-PEG-COOH nanoparticle or microparticle suspension (10 μg/mL in Dnsase RNase-free water) was incubated with 200 μL of 400 mmol/L 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 200 μL of 100 mmol/L N-hydroxysuccinimide (NHS) for 15 minutes at room temperature with gentle stirring. The resulting NHS-activated particles were covalently linked to 50 μL of 3'-NH2-modified A10 PSMA aptamer (ref. 9; 1 μg/μL in Dnsase RNase-free water) or 3'-NH2 and 5'-FITC-modified A10 PSMA aptamer where indicated. The resulting aptamer-nanoparticle bioconjugates were washed, resuspended, and preserved in suspension form in DNase RNase-free water. The conjugation of 5'-FITC and 3'-NH2-modified A10 PSMA aptamer to PLA-PEG-COOH nanoparticles and microparticles (0.5 mg/mL) was analyzed with the FACScan flow cytometer (Becton Dickinson, San Jose, CA) and fluorescent microscopy, respectively.

Cellular Binding and Uptake Studies. The prostate LNCaP and PC3 cell lines were grown in chamber slides in RPMI 1640 and Ham's F12K medium, respectively, supplemented with 100 units/mL aqueous penicillin G, 100 μg/mL streptomycin, and 10% fetal bovine serum at concentrations to allow 70% confluence in 24 h (i.e., LNCaP: 40,000 cells/cm²). On the day of experiments, cells were washed with prewarmed PBS and incubated with prewarmed phenol-red-reduced OptiMEM media for 30 minutes before the addition of 50 μg of nanoparticle-aptamer bioconjugates. Cells were incubated for 75 minutes to 16 hours at 37°C, washed with PBS three times, fixed with 4% paraformaldehyde, counterstained with 4',6-diamidino-2-phenylindole and Alexa-Flour Phalloidin, mounted, and visualized by fluorescent microscopy.

Prostate Cancer Tissue Staining. After antigen retrieval, formalin-fixed, paraffin-embedded prostate cancer tissue slides (Clinomics Biosciences, Watervliet, NY) were incubated with biotin-labeled A10 PSMA aptamer in 1 mL of PBS in the presence of 5× molar excess of tRNA and 0.2% BSA for 30 minutes at 37°C. Slides were washed with PBS three times and incubated with horseradish peroxidase-conjugated streptavidin for 1 hour, washed with PBS twice, incubated with the peroxidase substrate, washed with PBS twice, mounted, and analyzed by light microscopy.

Results and Discussion

Development of Controlled Release Polymer Drug Delivery Vehicles Suitable for Conjugation to Aptamers. We chose to generate particles with PLA and its derivatives. Particles that are generated from PLA are expected to have a neutral to slightly negative surface charge, a desirable characteristic because particles with a positive surface charge may nonspecifically interact with the negatively charged aptamers and diminish their binding characteristics. We hypothesized that by modifying the terminal ends of polymers with a hydrophilic carboxylic acid functional group, we may provide additional negative charge on particles that could repel the similarly charged aptamers and minimize charge interaction between the aptamers and particle surface. In addition, the presence of the carboxylic acid group on the particle surface would allow an easy conversion to NHS ester for covalent linkage to NH2-modified aptamers. We also decided to incorporate PEG in generating pegylated nanoparticle-aptamer bioconjugates. PEG has been shown to prolong nanoparticle circulating half-life (15), presumably because of the ability of PEG to reduce nonspecific adsorption of biomacromolecules such as proteins and nucleic acid (16). This latter characteristic may also contribute to minimizing nonspecific interaction of conjugated aptamers with the nanoparticle surface.

We used the following two polymer systems to generate nanoparticles and microparticles: PLA and pegylated PLA with a terminal carboxylic acid functional group (PLA-PEG-COOH). Particles were characterized for their size, surface charge (ζ potential), and surface morphology with Quasi-elastic laser light scattering, ZetaPALS dynamic light scattering detector, and scanning electron microscopy, respectively. The nanoparticles generated from both polymer systems showed narrow size distribution (polydispersity index < 0.1). The ζ potential of the PLA-PEG-COOH nanoparticles and microparticles were significantly more negative than the unmodified PLA particles as predicted (~50 ± 3 mV, mean ± SD, n = 3). The surface morphology and size distribution of particles from both polymer systems were determined by scanning electron microscopy, and representative images of PLA-PEG-COOH nanoparticles and microparticles were shown (Fig. 1).
Apt (EDC, particles that were incubated but had no covalent linkage to aptamers) or converted to NHS ester (EDC) or incubated with streptavidin-horse-radish peroxidase for 10 minutes, washed with PBS twice, incubated with the peroxidase substrate, washed with PBS twice, mounted, and analyzed by light microscopy. Cells which express the PSMA protein are stained in brown.

Development of Nanoparticle-Aptamer Bioconjugate for Targeted Drug Delivery to Prostate Cancer Cells. Two RNA aptamers were previously selected against the extracellular region of the PSMA protein (9). One aptamer, A10, has 2′-fluoro-modified ribose on all pyrimidines and a 3′-inverted deoxystymidine cap, which together confer significant nuclease resistance to this molecule. Because we are interested in developing a methodology for using aptamers to target the delivery of controlled released polymer particles to specific cells together with the fact that PSMA represents a well-characterized target of significant importance in prostate cancer, we used the A10 PSMA aptamer to generate our nanoparticle-aptamer bioconjugates. We demonstrated that consistent with the original report (9), the binding activity of A10 PSMA aptamer is restricted to LNCaP cells, which express the PSMA but not PC3 cells, which do not express the PSMA protein (data not shown). We then demonstrated that the A10 aptamer binds to the acinar epithelial cells of prostate cancer tissue consistent with the expected pattern of PSMA expression in the prostate gland (Fig. 2).

Using the PLA-PEG-COOH nano- and microparticles and the A10 PSMA aptamer, we generated nanoparticle-aptamer and microparticle-aptamer bioconjugates for the assessment of our conjugation strategy (Fig. 3A). To examine the presence of the aptamers on the particle surface, we used A10 PSMA aptamer with a 5′-FITC-label and a 3′-NH₂ modification to yield fluorescent nanoparticle-aptamer and microparticle-aptamer bioconjugates. The acid group on the particle surface was first converted to NHS ester in the presence of EDC and subsequently was covalently coupled to the amine-modified aptamer. To assess the specificity of aptamer interaction with the particle surface, we incubated aptamers with nanoparticles and microparticles without the conversion of carboxylic acid to NHS ester (i.e., absence of EDC); thus, any interaction would be nonspecific (i.e., charge or hydrogen bond interaction). The microparticle-aptamer bioconjugates were characterized by microscopy (Fig. 3B) and given the size limitations, the nanoparticle-aptamer bioconjugates were characterized by flow cytometry (Fig. 3C). These data demonstrate the specificity of our conjugation reaction.

Nanoparticle-Aptamer Bioconjugates Selectively and Efficiently Deliver Drugs to Targeted Cells. Through time course studies, we next demonstrated that the binding of pegylated nanoparticle-aptamer bioconjugates to LNCaP cells was significantly enhanced when compared with control pegylated nanoparticles lacking the A10 PSMA aptamer (Fig. 4A, top). In the case of PC3 prostate epithelial cells, which do not express the PSMA protein, no measurable difference in binding was observed between the bioconjugate and the control group (Fig. 4A, bottom). The number of nanoparticles attaching to representative cells after 75 minutes incubation of bioconjugates or control nanoparticles with LNCaP or PC3 cells was quantified by fluorescent microscopy. The data demonstrates a 77-fold enhancement in the binding of bioconjugates versus the control group in LNCaP cells (13.25 ± 7.56 versus 0.17 ± 0.45 nanoparticles per cell for bioconjugates versus control group, respectively; mean ± SD, n = 150, P < 0.001). A notable observation was a remarkably low binding efficiency of nanoparticles in nontargeted PC3 cells (0.03 ± 0.18 versus 0.30 ± 0.62 nanoparticles per cell for bioconjugates versus control group; mean ± SD, n = 150), presumably attributed to the presence of the PEG group (16, 17). The binding of bioconjugates to LNCaP cells was clearly detectable at the early time points; however, by 16 hours, the differential binding of nanoparticle-aptamer bioconjugates versus control group became markedly pronounced.

An antibody-mediated enhancement in the rate of PSMA endocytosis in LNCaP cells had previously been reported (18), and we were able to detect a measurable but a relatively modest enhancement in the
rate of PSMA endocytosis in response to the A10 PSMA aptamer binding to LNCaP cells.7 We next examined if the binding of bioconjugates to LNCaP cells results in particle uptake. Using z-axis fluorescent microscopy and three-dimensional image reconstruction, we studied the localization of the nanoparticle-aptamer bioconjugates after incubation with LNCaP cells. The data demonstrate that even at 2 hours, the particles were largely internalized into cells (Fig. 4B).

This differential uptake of bioconjugates by LNCaP versus PC3 cells was reproducibly observed with different passages of cells and nanoparticle-aptamer bioconjugate preparations.

In summary, aptamers are quickly emerging as a powerful class of ligands with utility in therapeutic applications. Specialized delivery vehicles that use these molecules for targeted delivery will likely have a role in future therapeutic modalities (19, 20). In this article, we have developed controlled release polymer drug delivery vehicles suitable for conjugation to aptamers and developed, as proof of concept, nanoparticle-aptamer bioconjugates, which target and are taken up by prostate cancer epithelial cells. These vehicles are potentially suitable for efficient and specific targeted delivery of chemotherapeutic drugs to prostate cancer cells, and additional in vivo studies are needed to determine the biodistribution of these vehicles after systemic administration. Once these vehicles are optimized, we postulate that a similar strategy may be used to develop nanoparticle aptamer bioconjugates for targeted drug delivery to a myriad of important human diseases.

Acknowledgments

We thank Shulamit Levenberg, Daniel Anderson, Daniel Kohane, and Yadong Wang for helpful discussions.

References


13. Leach F. Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface? Cancer Biol Ther 2004;3:


Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells


Cancer Res 2004;64:7668-7672.

Updated version Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/64/21/7668

Cited articles This article cites 18 articles, 7 of which you can access for free at: http://cancerres.aacrjournals.org/content/64/21/7668.full.html#ref-list-1

Citing articles This article has been cited by 25 HighWire-hosted articles. Access the articles at: /content/64/21/7668.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.